IP Library Granted Patent US 10,494,398
Granted Patent B2
US 10,494,398 · App. 15/616,751 · Granted Dec 3, 2019

Phosphorodiamidate backbone linkage for oligonucleotides

Inventors: Krisztina Pongracz (Oakland, CA); Mahesh Ramaseshan (Sunnyvale, CA)
Assignee: Geron Corporation
C07H21/00C07H1/00C07H19/10C07H19/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,494,398
App. No.
15/616,751
Granted
Dec 3, 2019
Kind
B2
Abstract

This invention relates to antisense oligonucleotides comprising at least one N3′→P5′ phosphorodiamidate linkage (NPN) in the backbone, useful for modulating gene expression involved in the pathogenesis of a disease. Compounds useful as building blocks of said antisense oligonucleotides and methods of preparing building block compounds including NPN linkages are provided.

Claims (58)

1. A compound of formula (II):

wherein

R 1 is an acid labile amino protecting group;

R 3 is independently selected from hydrogen, hydroxyl, and —O—R 3a ;

wherein R 3a is C 1-6 alkyl or C 1-6 alkyl substituted with —NR 3b R 3c , imidazolyl, —(CH 2 ) a O(CH 2 ) b NR 3b R 3c , or —(CH 2 ) a ONR 3d (CH 2 ) b NR 3b R 3c ;

wherein R 3b is hydrogen or C 1-2 alkyl;

R 3c is hydrogen or C 1-2 alkyl;

R 3d is hydrogen or C 1-2 alkyl;

a is an integer selected from one to 4;

b is an integer selected from one to 4;

R 4 is C 1-6 alkyl or C 1-6 alkyl substituted with —NR 4a R 4b ;

wherein R 4a is hydrogen or C 1-2 alkyl and R 4b is hydrogen or C 1-2 alkyl;

R 5 is C 1-6 alkyl or C 1-6 alkyl substituted with —NR 5a R 5b ;

wherein R 5a is hydrogen or C 1-2 alkyl and R 5b is hydrogen or C 1-2 alkyl; or

R 4 and R 5 taken together with the nitrogen to which they are attached form a monocyclic heterocyclyl or a monocyclic heterocyclyl substituted with C 1-6 alkyl, sperminyl or spermidinyl;

R 6 is a leaving group;

W is independently selected from O, S, and Se; and

B 1 is a heterocyclic base moiety or a protected heterocyclic base moiety;

or a salt thereof.

2. The compound of claim 1 , or a salt thereof, wherein W is O.

3. The compound of claim 1 , or a salt thereof, wherein B 1 is selected from purinyl and pyrimidinyl.

4. The compound of claim 1 , or a salt thereof, wherein B 1 is selected from 4-benzoyl-1-cytosinyl, 6-benzoyl-9-adeninyl, 6-dimethylformamidino-9-adeninyl, 2-isobutyryl-9-guaninyl, 2-dimethylformamidino-9-guaninyl, 9-adeninyl, 9-guaninyl, 1-cytosinyl, 1-thyminyl and 1-uracilyl.

5. The compound of claim 1 , or a salt thereof, wherein B 1 is selected from 9-adeninyl, 9-guaninyl, 1-cytosinyl, 1-thyminyl and 1-uracilyl.

6. The compound of claim 1 , or a salt thereof, wherein R 3 is hydrogen.

7. The compound of claim 1 , or a salt thereof, wherein R 4 and R 5 are methyl.

8. The compound of claim 1 , or a salt thereof, wherein R 1 is selected from trityl, dimethoxytrityl and methoxytrityl.

9. The compound of claim 1 , or a salt thereof, wherein R 6 is selected from chloro, iodo, bromo, fluoro, methanesulfonyloxy, tosyloxy, triflyloxy, nitro-phenylsulfonyloxy and bromo-phenylsulfonyloxy.

10. The compound of claim 1 , or a salt thereof, wherein R 6 is halo.

11. The compound of claim 1 , or a salt thereof, wherein R 1 is selected from trityl, dimethoxytrityl and methoxytrityl and R 6 is halo.

12. The compound of claim 1 , or a salt thereof, wherein the compound is selected from:

13. A method of preparing a compound of formula (II):

wherein

R 1 is an acid labile amino protecting group;

R 3 is independently selected from hydrogen, hydroxyl, and —O—R 3a ;

wherein R 3a is C 1-6 alkyl or C 1-6 alkyl substituted with —NR 3b R 3c , imidazolyl, —(CH 2 ) a O(CH 2 ) b NR 3b R 3c , or —(CH 2 ) a ONR 3d (CH 2 ) b NR 3b R 3c ;

wherein R 3b is hydrogen or C 1-2 alkyl;

R 3c is hydrogen or C 1-2 alkyl;

R 3d is hydrogen or C 1-2 alkyl;

a is an integer selected from one to 4;

b is an integer selected from one to 4;

R 4 is C 1-6 alkyl or C 1-6 alkyl substituted with —NR 4a R 4b ;

wherein R 4a is hydrogen or C 1-2 alkyl and R 4b is hydrogen or C 1-2 alkyl;

R 5 is C 1-6 alkyl or C 1-6 alkyl substituted with —NR 5a R 5b ;

wherein R 5a is hydrogen or C 1-2 alkyl and R 5b is hydrogen or C 1-2 alkyl; or

R 4 and R 5 taken together with the nitrogen to which they are attached form a monocyclic heterocyclyl or a monocyclic heterocyclyl substituted with C 1-6 alkyl, sperminyl, or spermidinyl;

R 6 is a leaving group;

W is independently selected from O, S, and Se; and

B 1 is a heterocyclic base moiety or a protected heterocyclic base moiety;

or a salt thereof;

wherein the method comprises:

a) contacting a compound of formula (A)

with a phosphorylating reagent having the formula:

14. The method of claim 13 , wherein R 4 and R 5 are methyl.

15. The method of claim 13 , wherein R 1 is selected from trityl, dimethoxytrityl and methoxytrityl.

16. The method of claim 13 , wherein R 6 is selected from chloro, iodo, bromo, fluoro, methanesulfonyloxy, tosyloxy, triflyloxy, nitro-phenylsulfonyloxy and bromo-phenylsulfonyloxy.

17. The method of claim 13 , wherein R 6 is halo.

18. The method of claim 14 , wherein the phosphorylating agent is dimethylamino-phosphorodichioridate.

19. The method of claim 14 , wherein the phosphorylating agent is thiophosphorodichloridate or selenophosphorodichloridate.

Assignments (2)
PATENT SECURITY AGREEMENT Recorded Nov 12, 2024
From: GERON CORPORATION
To: BIOPHARMA CREDIT PLC [COLLATERAL AGENT]
Reel/Frame 069341/0832 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2017
From: PONGRACZ, KRISZTINA; RAMASESHAN, MAHESH
To: GERON CORPORATION
Reel/Frame 043300/0613 →
Continuity (3)
Continuation 14498872 · Sep 26, 2014
Provisional Application 61884848 · Sep 30, 2013
Related Publication 20180002367A1 · Jan 4, 2018